Novartis Pharmaceuticals Australia Pty Limited (ACN 004 244 160) and its related bodies corporate (we) processes personal information about you to provide you with products and services and to provide information which we think may be of interest to you...
Medical Information Request
- MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS). 2 Novartis conducted a large Phase III trial, called EXPAND, to investigate MAYZENT ® in SPMS. 1,2 PI CMI EXPAND study design and baseline...Twitter Linkedin Facebook Pinterest Google plus
- HEART FAILURE: A GP DISEASE STATE A guide to optimising your patient’s treatment Full version. Ideal for Dinner Meeting (60 + minutes) Download document HEART FAILURE: A GP DISEASE STATE A guide to optimising your patient’s treatment Short version. Ideal...Twitter Linkedin Facebook Pinterest Google plus
- Reference Study Name Title File 10 Myelination MRI diffusion metrics are sensitive to changes in fingolimod treatment https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS20... 10 Myelination Sensitivity of magnetic resonance imaging to...
- View informative resources and expert opinions on how to select, prepare and manage patients on KYMRIAH. Indication and Funding Criteria Patient Management This resource contains helpful information on patient management including patient eligibility,...Twitter Linkedin Facebook Pinterest Google plus
- Perspectives on patient care in ITP Are we doing everything we can for patients with ITP? Introducing I-WISh, a collaboration among Global ITP experts, patient groups and Novartis aiming to uncover the impact of ITP on daily life and patient perceptions...Twitter Linkedin Facebook Pinterest Google plus